RxDoctor Payments Data

Zafar Mahmood, MD

Psychiatry · Kansas City, MONPI 1952361545

Payments from drug & device makers

$4,656in general payments, 2019–2025

Across 295 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$932
  • Otsuka America Pharmaceutical, Inc.$702
  • AbbVie$638
  • Teva Pharmaceuticals USA, Inc.$472
  • Johnson & Johnson$462
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$395
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$4,51497%
  • Education$1413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,656 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$14,536
Medicare patients
56
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate15$49,040
TrintellixVortioxetine Hydrobromide55$31,394
RexultiBrexpiprazole17$27,086
FanaptIloperidone14$26,489
VraylarCariprazine Hcl14$18,692
CaplytaLumateperone Tosylate11$18,055
Lurasidone Hcl57$10,400
Clozapine OdtClozapine28$9,106
Divalproex Sodium ErDivalproex Sodium134$5,172
Fluphenazine Hcl26$5,121
Clozapine48$3,545
Clonazepam212$2,783
Bupropion XlBupropion Hcl85$2,187
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine57$2,040
Aripiprazole83$1,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$462$49,04015 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$63$31,39455 claims
Otsuka America Pharmaceutical, Inc.Rexulti$702$27,08617 claims
Vanda Pharmaceuticals Inc.Fanapt$166$26,48914 claims
AbbVieVraylar$638$18,69214 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$395$18,05511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →